Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

Title:Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

Volume: 13 Issue: 10

Author(s): Asif Khurshid Qazi, Aashiq Hussain, Abid Hamid, Yasrib Qurishi, Rabiya Majeed, Mudassier Ahmad, Rauf Ahmad Najar, Javeed Ahmad Bhat, Shashank Kumar Singh, Mohmmad Afzal Zargar, Shakir Ali and Ajit Kumar Saxena

Affiliation:

Keywords: Anticancer target, cancer, inhibitors, PI3K-Akt-mTOR, Signaling, therapy, translation.

Abstract: Cancer is a diverse class of diseases which differ widely in their cause and biology. The aberrant behavior of cancer reflects up regulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Phosphoinositide-3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls various biological processes that are important for normal functioning of the cell via cell cycle progression, survival, migration, transcription, translation and metabolism. However, PI3K signaling pathway is dysregulated almost in all cancers which is due to the amplification and genetic mutation of PI3K gene, encoding catalytic and regulatory subunit of PI3K isoforms. The current review focuses on the structural features of various PI3K isoforms including Akt and mTOR and their inhibition using specific small molecule inhibitors in an attempt to achieve an attractive target for cancer prevention and chemotherapy.

Cite this article as:

Qazi Khurshid Asif, Hussain Aashiq, Hamid Abid, Qurishi Yasrib, Majeed Rabiya, Ahmad Mudassier, Najar Ahmad Rauf, Bhat Ahmad Javeed, Singh Kumar Shashank, Zargar Afzal Mohmmad, Ali Shakir and Saxena Kumar Ajit, Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (10) . https://dx.doi.org/10.2174/1871520613666131125123241